GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shenzhen Hepalink Pharmaceutical Group Co 002399.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

9.32

-1.27%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shenzhen Hepalink Pharmaceutical Group Co

Its shares trade on Shenzhen under the ticker 002399.SZ. It has been listed since 6 May 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥5.48bn and net income of CN¥349.5m. At that date it held total assets of CN¥16.63bn and shareholders' equity of CN¥12.03bn.

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company. The firm operates four segments. The Pharmaceutical Preparation segment is engaged in the production and sales of anticoagulant and antithrombotic pharmaceutical preparations, including enoxaparin sodium injection and heparin sodium injection. The Active Pharmaceutical Ingredient (API) segment operates the production and sales of API products, including enoxaparin sodium API and heparin sodium API. The contract development manufacturing organization (CDMO) segment provides full-cycle services for the process of developing drugs, including research and development, production, quality management, project management and commercialization. The firm also operates Other segment.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
6 May 2010
Employees
2,162

Leadership

Pay as last reported

  • Mr. Li LiChairman of the Board, since 1998CN¥3.0m
  • Ms. Juan ChenChief Financial OfficerCN¥992,600
  • Mr. Yu ShanGeneral Manager, Director, since 1998CN¥2.6m
  • Ms. Tan LiDeputy General Manager, Director, since 1998CN¥2.5m
  • Mr. Fengqi QianSecretary of the Board, Joint Company SecretaryCN¥1.7m
  • Mr. Ping ZhangDirectorCN¥3.5m
  • Mr. Peng HuangIndependent DirectorCN¥58,300
  • Mr. Chuan LuIndependent DirectorCN¥100,000
  • Mr. Ming YiIndependent DirectorCN¥58,300

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
72
Environment
82
Social
64
Governance
69
Direct emissions (scope 1)
18,284 t
Energy emissions (scope 2)
33,329.7 t
Women in the workforce
40.43011%
Carbon reduction policy
No
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Shenzhen Hepalink Pharmaceutical Group Co Ltd has several strengths that contribute to its success:

Weaknesses

  • Despite its strengths, Shenzhen Hepalink Pharmaceutical Group Co Ltd also faces certain weaknesses:

Opportunities

  • Shenzhen Hepalink Pharmaceutical Group Co Ltd can leverage several opportunities to further expand its business:

Threats

  • Several external factors pose threats to the success of Shenzhen Hepalink Pharmaceutical Group Co Ltd:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.